Compare GSK plc (GSK) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? GSK plc trades at $50.37 (market cap $102.60B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.65. The key difference: GSK plc pays a 3.57% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and GSK plc is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| GSK | QDTE | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $36.60 |
52-Week Low | $38.96 | $26.85 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
QDTE trades at $29.80, up 0.51% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The fund faces scrutiny over its high distribution yield, which is reportedly funded by return of capital, leading to net asset value erosion. Recent news highlights underperformance in bull markets and concerns about the sustainability of its weekly payout strategy.
The outlook is cautious due to structural risks in the covered call strategy, with potential for continued NAV decline outweighing the attractive yield. Investors should weigh the income benefits against the risk of capital depletion, as analyst sentiment has turned negative with recent downgrades emphasizing the fund's vulnerability to market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
